CompletedNot Applicable

Continuous Monitoring of Vital Signs at Home (WARD HOME II)

Denmark83 participantsStarted 2023-10-03

Plain-language summary

The study aims to investigate the use of wireless, continuous monitoring in patients at home including the frequency of alarms triggered by abnormal vital parameters and their significance for (re)hospitalisation/Serious Adverse Events(SAE) and/or death within 30 days.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Adult patients (≥18 years) admitted (with at least one night stay) with an acute medical disease and scheduled for discharge to their own homes Adult patients (≥18 years) who have contacted the EMS and, after assessment by paramedic personnel, not deemed sick enough for immediate hospital admission. Exclusion Criteria: Patients placed on palliative treatment. Acceptable chronically abnormal vital parameters of SpO2\<88%, MAP\<70, RR\>24, or HR\>110. Allergy to plaster, plastic, or silicone. A pacemaker or Implantable Cardioverter Defibrillator (ICD) device. If the patient was deemed not able to open the front door when visited by the investigator. Inability to give informed consent.

What they're measuring

(Re)admission

Timeframe: within 30 days

Serious Adverse Events

Timeframe: within 30 days

Mortality

Timeframe: within 30 days

Trial details

NCT IDNCT06077851

SponsorBispebjerg Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-10-30

View on ClinicalTrials.gov More Vital Sign Monitoring trials